{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:31:29Z","timestamp":1791549089072,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolic syndrome (MetS) and obesity represent a public health problem worldwide. Bioelectrical impedance analysis (BIA) is a practical and effective way of evaluating body composition, especially abdominal fat. Liraglutide, a GLP-1 analog, reduces body weight and improves cardiometabolic parameters. In this prospective non-randomized intervention study, we evaluated the effect of 6\u00a0months of treatment with liraglutide (n\u2009=\u200957) on the clinical, laboratory and BIA findings of adult sex-stratified patients diagnosed with obesity and MetS, compared to a control group receiving sibutramine (n\u2009=\u200946). The groups were statistically similar with regard to the age of females (<jats:italic>p<\/jats:italic>\u2009=\u20090.852) and males (<jats:italic>p<\/jats:italic>\u2009=\u20090.657). Almost all anthropometric and BIA variables were higher in the treatment group than in the comparative group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Abdominal circumference (AC) decreased significantly more in the treatment group. In males, body weight and fat mass also decreased (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Liraglutide treatment was associated with a greater reduction in trunk fat mass (FMT) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). AC and FMT were strongly correlated (rho\u2009=\u20090.531, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in the treatment group. In the multiple regression analysis, liraglutide treatment remained independently associated with FMT. Treatment with liraglutide for 6\u00a0months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes.<\/jats:p>","DOI":"10.1038\/s41598-023-40366-4","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:02:22Z","timestamp":1691769742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-4456","authenticated-orcid":false,"given":"Frederico Perboyre Carioca","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-6782","authenticated-orcid":false,"given":"Carlos Ewerton Maia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"40366_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4158\/EP13263.RA","volume":"19","author":"WT Garvey","year":"2013","unstructured":"Garvey, W. T. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approach. Endocr. Pract. 19, 864\u2013874 (2013).","journal-title":"Endocr. Pract."},{"key":"40366_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13098-017-0242-0","volume":"9","author":"MC Mancini","year":"2017","unstructured":"Mancini, M. C. & de Melo, M. E. The burden of obesity in the current world and the new treatments available: Focus on liraglutide 3.0\u00a0mg. Diabetol. Metabol. Syndr. 9, 44 (2017).","journal-title":"Diabetol. Metabol. Syndr."},{"issue":"36","key":"40366_CR3","doi-asserted-by":"publisher","first-page":"e4806","DOI":"10.1097\/MD.0000000000004806","volume":"95","author":"JS Neergaard","year":"2016","unstructured":"Neergaard, J. S. et al. Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women. Medicine. 95(36), e4806 (2016).","journal-title":"Medicine."},{"key":"40366_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/ATVBAHA.107.159228","volume":"28","author":"JP Despr\u00e9s","year":"2008","unstructured":"Despr\u00e9s, J. P. et al. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039\u20131049 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"40366_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/1471-2458-13-1198","volume":"13","author":"FC Vidigal","year":"2013","unstructured":"Vidigal, F. C., Bressan, J., Babio, N. & Salas-Salvad\u00f3, J. Prevalence of metabolic syndrome in Brazilian adults: A systematic review. BMC Public Health 13, 1198 (2013).","journal-title":"BMC Public Health"},{"key":"40366_CR6","first-page":"863","volume":"34","author":"SR Anxela","year":"2017","unstructured":"Anxela, S. R. et al. Metabolic syndrome and visceral fat in women with cardiovascular risk factor. Nutr. Hosp. 34, 863\u2013868 (2017).","journal-title":"Nutr. Hosp."},{"key":"40366_CR7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131\u20132157 (2007).","journal-title":"Gastroenterology"},{"key":"40366_CR8","first-page":"R1541","volume":"276","author":"JP Gutzwiller","year":"1999","unstructured":"Gutzwiller, J. P. et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276, R1541\u2013R1544 (1999).","journal-title":"Am. J. Physiol."},{"key":"40366_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"330","author":"A Keymann","year":"1987","unstructured":"Keymann, A., Ghatei, M. A. & Williams, G. Glucagon like peptide-1 7\u201336: A physiological incretin in man. Lancet. 330, 1300\u20131304 (1987).","journal-title":"Lancet."},{"key":"40366_CR10","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","volume":"51","author":"PE MacDonald","year":"2002","unstructured":"MacDonald, P. E. et al. The multiple actions of GLP-1 on the process of glucosestimulated insulin secretion. Diabetes 51, S434\u2013S442 (2002).","journal-title":"Diabetes"},{"key":"40366_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1210\/endo.140.1.6421","volume":"140","author":"K Meeran","year":"1999","unstructured":"Meeran, K. et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7\u201336) amide or exendin-(9\u201339) alters body weight in the rat. Endocrinology 140, 244\u2013250 (1999).","journal-title":"Endocrinology"},{"key":"40366_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/MCO.0b013e32832da22c","volume":"12","author":"MY Jaffrin","year":"2009","unstructured":"Jaffrin, M. Y. Body composition determination by bioimpedance: An update. Curr. Opin. Clin. Nutr. Metab. Care 12, 482\u2013486 (2009).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"40366_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2310\/JIM.0b013e318244e2d9","volume":"60","author":"H Ozhan","year":"2012","unstructured":"Ozhan, H. et al. Performance of bioelectrical impedance analysis in the diagnosis of metabolic syndrome. J. Investig. Med. 60, 587\u2013591 (2012).","journal-title":"J. Investig. Med."},{"key":"40366_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3904\/kjim.2018.427","volume":"36","author":"HH Jeon","year":"2021","unstructured":"Jeon, H. H. et al. Risk for metabolic syndrome in the population with visceral fat area measured by bioelectrical impedance analysis. Korean J. Intern. Med. 36, 97\u2013105 (2021).","journal-title":"Korean J. Intern. Med."},{"key":"40366_CR15","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","volume":"284","author":"World Medical Association","year":"2000","unstructured":"World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 284, 3043\u20133045 (2000).","journal-title":"JAMA"},{"key":"40366_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti, K. G. M. M. et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation 120, 1640\u20131645 (2009).","journal-title":"Circulation"},{"key":"40366_CR17","unstructured":"Novo Nordisk Inc. Saxenda\u00ae (Inje\u00e7\u00e3o de liraglutida [origem do DNAr]) Informa\u00e7\u00f5es completas sobre prescri\u00e7\u00e3o. http:\/\/www.novo-pi.com\/saxenda.pdf."},{"key":"40366_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1345\/aph.18319","volume":"33","author":"CA Luque","year":"1999","unstructured":"Luque, C. A. & Rey, J. A. Sibutramine: A serotonine-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. 33, 968\u2013978 (1999).","journal-title":"Ann. Pharmacother."},{"key":"40366_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","volume":"54","author":"FC Bull","year":"2020","unstructured":"Bull, F. C. et al. World Health Organization 2020 guidelines on physical activity and sedentary behavior. Br. J. Sports Med. 54, 1451\u20131462 (2020).","journal-title":"Br. J. Sports Med."},{"key":"40366_CR20","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 36, 1953\u20132041 (2018).","journal-title":"J. Hypertens."},{"key":"40366_CR21","unstructured":"OTTOBONI. Aparelho de Bioimped\u00e2ncia modelo InBody270. Dispon\u00edvel em: https:\/\/ottoboni.com.br\/produtos\/inbody-270\/."},{"key":"40366_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.clnu.2004.06.004","volume":"23","author":"UG Kyle","year":"2004","unstructured":"Kyle, U. G. et al. Bioelectrical impedance analysis\u2014Part I: Review of principles and methods. Clin. Nutr. 23, 1226\u20131243 (2004).","journal-title":"Clin. Nutr."},{"key":"40366_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023780","volume":"100","author":"JS Park","year":"2021","unstructured":"Park, J. S., Kwon, J., Choi, H. J. & Lee, C. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine 100, e23780 (2021).","journal-title":"Medicine"},{"key":"40366_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup, A. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond.). 36, 843\u2013854 (2012).","journal-title":"Int. J. Obes. (Lond.)."},{"key":"40366_CR25","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low caloric diet induced weight loss: The SCALE maintenance ranzomized study. Int. J. Obes. 37, 1443\u20131451 (2013).","journal-title":"Int. J. Obes."},{"key":"40366_CR26","first-page":"1","volume":"18","author":"N Peradze","year":"2018","unstructured":"Peradze, N. et al. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: A randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc. Diabetol. 18, 1\u201312 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"40366_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/oby.22462","volume":"27","author":"S Wharton","year":"2019","unstructured":"Wharton, S. et al. Real-world clinical effectiveness of liraglutide 3.0\u00a0mg for weight management in Canada. Obesity. 27, 917\u2013924 (2019).","journal-title":"Obesity."},{"key":"40366_CR28","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/jdi.13314","volume":"11","author":"CA Chou","year":"2020","unstructured":"Chou, C. A. & Chuang, S. F. Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. J. Diabetes Investig. 11, 1524\u20131531 (2020).","journal-title":"J. Diabetes Investig."},{"key":"40366_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Ssunier","year":"2015","unstructured":"Pi-Ssunier, X. et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","journal-title":"N. Engl. J. Med."},{"key":"40366_CR30","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/oby.21629","volume":"24","author":"K Fujioka","year":"2016","unstructured":"Fujioka, K. et al. Early treatment with liraglutide 3.0\u00a0mg predicts weight loss at 1\u00a0year and is associated with improvements in clinical markers. Obesity (Silver Spring) 24, 2278\u20132288 (2016).","journal-title":"Obesity (Silver Spring)"},{"key":"40366_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40519-019-00815-4","volume":"26","author":"O Bosello","year":"2021","unstructured":"Bosello, O. & Vanzo, A. Obesity paradox and aging. Eat Weight Disord. 26, 27\u201335 (2021).","journal-title":"Eat Weight Disord."},{"key":"40366_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-1-4613-1473-8_51","volume-title":"In Vivo Studies of Body Composition","author":"HC Lukaski","year":"1990","unstructured":"Lukaski, H. C. Applications of bioelectrical impedance analysis: A critical review. In In Vivo Studies of Body Composition (eds Yasumura, S. et al.) 365\u2013374 (Springer, 1990)."},{"key":"40366_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.clnu.2004.09.012","volume":"23","author":"UG Kyle","year":"2004","unstructured":"Kyle, U. G. et al. Bioelectrical impedance analysis\u2014Part II: Utilization in clinical practice. Clin. Nutr. 23, 1430\u20131453 (2004).","journal-title":"Clin. Nutr."},{"key":"40366_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1152\/jappl.1986.60.4.1327","volume":"60","author":"HC Lukaski","year":"1986","unstructured":"Lukaski, H. C., Bolonchuk, W. W., Hall, C. B. & Siders, W. A. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J. Appl. Physiol 60, 1327\u201332 (1986).","journal-title":"J. Appl. Physiol"},{"key":"40366_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1590\/S0004-27302013000100004","volume":"57","author":"M Erickemberg","year":"2013","unstructured":"Erickemberg, M., Oliveira, C. C., Roriz, A. K. L. C., Mello, A. L. & Sampaio, L. R. Bioelectrical impedance and visceral fat: A comparison with computed tomography in adults and elderly. Arq. Bras. Endocrinol. Metabol. 57, 27\u201332 (2013).","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"40366_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.dsx.2021.02.018","volume":"15","author":"CM Bentes","year":"2021","unstructured":"Bentes, C. M. et al. Rebiability of BIOIMPEDANCE and indirect calorimetry to evaluate resting metabolic rate in Brazilian women with metabolic syndrome. Diabetes Metab. Syndr. 15, 493\u2013497 (2021).","journal-title":"Diabetes Metab. Syndr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40366-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:13:22Z","timestamp":1700396002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40366"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40366-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13090"}}